466 related articles for article (PubMed ID: 23175838)
1. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
[TBL] [Abstract][Full Text] [Related]
4. Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.
Li C; Götz J
EMBO J; 2017 Nov; 36(21):3120-3138. PubMed ID: 28864542
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.
Roberson ED; Halabisky B; Yoo JW; Yao J; Chin J; Yan F; Wu T; Hamto P; Devidze N; Yu GQ; Palop JJ; Noebels JL; Mucke L
J Neurosci; 2011 Jan; 31(2):700-11. PubMed ID: 21228179
[TBL] [Abstract][Full Text] [Related]
6. Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model.
Ali T; Klein AN; Vu A; Arifin MI; Hannaoui S; Gilch S
Cell Mol Life Sci; 2023 May; 80(6):139. PubMed ID: 37149826
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.
Um JW; Kaufman AC; Kostylev M; Heiss JK; Stagi M; Takahashi H; Kerrisk ME; Vortmeyer A; Wisniewski T; Koleske AJ; Gunther EC; Nygaard HB; Strittmatter SM
Neuron; 2013 Sep; 79(5):887-902. PubMed ID: 24012003
[TBL] [Abstract][Full Text] [Related]
8. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
Um JW; Strittmatter SM
Prion; 2013; 7(1):37-41. PubMed ID: 22987042
[TBL] [Abstract][Full Text] [Related]
10. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
Liu W; Zhao J; Lu G
Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
[TBL] [Abstract][Full Text] [Related]
11. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.
Vossel KA; Xu JC; Fomenko V; Miyamoto T; Suberbielle E; Knox JA; Ho K; Kim DH; Yu GQ; Mucke L
J Cell Biol; 2015 May; 209(3):419-33. PubMed ID: 25963821
[TBL] [Abstract][Full Text] [Related]
12. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
[TBL] [Abstract][Full Text] [Related]
13. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
14. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
Minami SS; Clifford TG; Hoe HS; Matsuoka Y; Rebeck GW
Neurobiol Aging; 2012 Apr; 33(4):825.e15-24. PubMed ID: 21741124
[TBL] [Abstract][Full Text] [Related]
15. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.
Liao D; Miller EC; Teravskis PJ
Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999
[TBL] [Abstract][Full Text] [Related]
16. Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn.
Wang H; Ren CH; Gunawardana CG; Schmitt-Ulms G
Mol Neurodegener; 2013 Jul; 8():24. PubMed ID: 23856335
[TBL] [Abstract][Full Text] [Related]
17. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines.
Xia D; Li C; Götz J
Biochim Biophys Acta; 2015 May; 1852(5):913-24. PubMed ID: 25558816
[TBL] [Abstract][Full Text] [Related]
18. Fyn depletion ameliorates tau
Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
Acta Neuropathol Commun; 2020 Jul; 8(1):108. PubMed ID: 32665013
[TBL] [Abstract][Full Text] [Related]
19. Fyn Kinase Controls Tau Aggregation In Vivo.
Briner A; Götz J; Polanco JC
Cell Rep; 2020 Aug; 32(7):108045. PubMed ID: 32814048
[TBL] [Abstract][Full Text] [Related]
20. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
